Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi Sankyo says Welchol is “new treatment option”

Daiichi Sankyo says Welchol is “new treatment option”

17th April 2008

A recently-approved Type 2 diabetes treatment has been added to the official drug recommendation list of two major organisations.

Welchol (colesevelam HCl), manufactured by Daiichi Sankyo, has been added to the American College of Endocrinology and American Association of Clinical Endocrinologists 2008 Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus.

The Road Maps aim to assist doctors with the effective treatment and management of patients.

Welchol was approved in January and is the only treatment that also treats high LDL-cholesterol, Daiichi Sankyo states.

Sukumar Nagendran, senior director of diabetes and metabolism at Daiichi Sankyo, said: “Welchol offers physicians a new treatment option that addresses two cardiovascular risk factors, elevated LDL-cholesterol and blood glucose in patients with type 2 diabetes.”

Based in Tokyo, Japan, Daiichi Sankyo was founded in 2005 and has more than 15,000 employees.

The company recently collaborated with Eli Lilley to develop Prasugrel, which both said cuts the risk of stent-related clots by more than half versus rival treatment Clopidogrel.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.